Angiotech CVC with Anti-microbial Surface
Angiotech CVC with Anti-microbial Surface
Central venous catheters ("CVC") are usually inserted into critically ill patients for extended periods of time to administer fluids, drugs, and nutrition, as well as facilitate frequent blood draws.
Through our proprietary drug identification strategy, we elected to evaluate 5-Fluorouracil ("5-FU"), as a compound that may help to prevent certain types of infection in patients receiving a CVC. We have conducted a human clinical trial in the United States designed to assess the safety and efficacy of our 5-FU-eluting CVC in preventing various types of catheter related infections.
The study was a randomized, single-blind, 960-patient, 25-center study and was designed to evaluate whether our 5-FU-eluting CVC prevents bacterial colonization. The study achieved it's primary endpoint with statistical significance.
We are currently developing a commercial launch plan for this product, as well as evaluating certain product line extensions relating to this technology.
Products
- Product Overview
- Quill™ device
- 5FU - CVC
- Interventional
- Biopsy
- Ophthalmic
- Surgical
- Angiotech Partner Solutions
- Private Label
Quick Links
© Copyright 2011 Angiotech. All Rights Reserved.